Engineering the protein corona on RNA nanoparticles for improved nucleic acids-based therapies delivery

Project description

Improving nanoparticle-based drug delivery

Recent advances in nanotechnology have paved the way for the use of nanoparticles in cancer therapy as drug delivery vehicles. Despite the advantages of nanoparticle drug delivery, including high selectivity and reduced toxicity, there are various aspects to the process that remain elusive, such as the acquisition of proteins upon in vivo injection. The EU-funded NanoRNA_PC project will employ state-of-the-art methodologies to characterise the protein corona formed on RNA nanoparticles upon interaction with biological components. Understanding the composition of the protein corona on nanoparticles is expected to improve their design as well as their biological outcome.

Fields of science

• natural sciences › physical sciences › optics › microscopy › super resolution microscopy
• medical and health sciences › medical biotechnology › nanomedicine
• medical and health sciences › clinical medicine › oncology
• natural sciences › biological sciences › genetics › RNA
• engineering and technology › nanotechnology › nano-materials

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2019 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2019

See other projects for this call

Funding Scheme

MSCA-IF-EF-SE - Society and Enterprise panel

Coordinator

SIXFOLD BIOSCIENCE LTD

Net EU contribution

€ 212 933,76

Address

The Imperial College White City Inc Innovation Hub
W12 0BZ London
United Kingdom

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 0,00